Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;14(1):2466699.
doi: 10.1080/22221751.2025.2466699. Epub 2025 Apr 6.

Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024

Claire Nour Abou Chakra  1   2 , François Blanquart  3 , Vincent Vieillefond  4 , Vincent Enouf  5 , Benoit Visseaux  6 , Stéphanie Haim-Boukobza  7 , Laurence Josset  8   9 , Marie-Anne Rameix-Welti  5   10   11 , Bruno Lina  8 , Marta C Nunes  1   12 ; RELAB Study group; Antonin Bal  8   9
Affiliations

Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024

Claire Nour Abou Chakra et al. Emerg Microbes Infect. 2025 Dec.

Abstract

The epidemiology of respiratory viruses and vaccine effectiveness (VE) in the community are not well described. This study assessed VE against a positive test of influenza (VEf) and SARS-CoV-2 (VECov). Data from networks of community-based laboratories in France were collected during standard of care in the 2023-2024 epidemic season (n = 511,083 multiplex RT-PCR tests). Patients' demographics and symptoms were reported in addition to viral sequencing results. The test-negative design was used to estimate VEf and VECov by time since vaccination and calendar week. Adjusted VEf by age, sex, presence of symptoms, PCR technique, and week of testing, was 47.6% (95% CI: 44.3-50.7%). VEf was lower in patients ≥65 years (42.0%; 95% CI: 36.6-46.9%) than in 18-64 years (52.9%; 95% CI: 48.6-56.8%). The adjusted VEf against type A influenza, which represented 98% of typed viruses, was 51% (45%-56.6%) for patients vaccinated 15 days to 3 months before testing, and 35.5% (24.2%-45.3%) for those vaccinated 3-6 months before testing. For VECov, the adjusted estimate in patients vaccinated 15 days to 3 months prior to testing was 40.6% (7.2%-58.6%) at week 39, 24.8% (4.0%-38.8%) at week 45, and dropped systematically through the epidemic season as the JN.1 variant became dominant. This study showed moderate VEf and VECov against infection in the community and highlighted the impact of time since vaccination and age for both estimates, and the new variant emergence on VECov. These findings should be considered in future vaccination campaigns.

Keywords: COVID-19; Community testing; Effectiveness; Influenza; Vaccine.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Flowchart for influenza testing, vaccination status, typing, and case selection for analyses.
Figure 2.
Figure 2.
Flowchart for SARS-CoV-2 testing, vaccination status, typing, and case selection for analyses.
Figure 3.
Figure 3.
Adjusted vaccine effectiveness against influenza overall and stratified.
Figure 4.
Figure 4.
Adjusted vaccine effectiveness against influenza by calendar weeks of testing and time since vaccination.
Figure 5.
Figure 5.
Adjusted vaccine effectiveness against SARS-CoV-2 by calendar weeks of testing and time since vaccination.
See this image and copyright information in PMC

References

    1. World Health Organization . European Respiratory Virus Surveillance Summary [Internet]. 2024. Available from: https://erviss.org/.
    1. Nørgaard SK, Nielsen J, Nordholm AC, et al. . Excess mortality in Europe coincides with peaks of COVID-19, influenza and respiratory syncytial virus (RSV), November 2023 to February 2024. Eurosurveillance. 2024;29(15):2400178. - PMC - PubMed
    1. Maurel M, Pozo F, Pérez-Gimeno G, et al. . Influenza vaccine effectiveness in Europe: results from the 2022–2023 VEBIS (vaccine effectiveness, burden and impact studies) primary care multicentre study. Influenza Resp Viruses. 2024;18(1):e13243. - PMC - PubMed
    1. Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gimeno G, Buda S, et al. . Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024;29(8):2400089. doi:10.2807/1560-7917.ES.2024.29.8.2400089 - DOI - PMC - PubMed
    1. Skowronski DM, Zhan Y, Kaweski SE, Sabaiduc S, Khalid A, Olsha R, et al. . 2023/24 mid-season influenza and omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN). Euro Surveill. 2024;29(7):2400076. doi:10.2807/1560-7917.ES.2024.29.7.2400076 - DOI - PMC - PubMed

MeSH terms